Long-Term Outcomes With Frontline Nilotinib vs Imatinib in Newly Diagnosed CML in Chronic Phase
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 10-Year Analysis
Leukemia 2021 Jan 07;[EPub Ahead of Print], HM Kantarjian, TP Hughes, RA Larson, DW Kim, S Issaragrisil, P le Coutre, G Etienne, C Boquimpani, R Pasquini, RE Clark, V Dubruille, IW Flinn, S Kyrcz-Krzemien, E Medras, M Zanichelli, I Bendit, S Cacciatore, K Titorenko, P Aimone, G Saglio, A HochhausFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.